Filana Therapeutics, Inc. (FLNA) stock forecast & analysis
0.8752
NasdaqCM · USD
Down: -0.1548, -15.0%
1 analysis
- Open
- 1.00
- Previous close
- 1.03
- Day range
- 0.8701 – 1.00
- 52-week range
- 0.6700 – 4.98
- Volume (shares)
- 1.24M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 48.31M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- -0.70
- Market cap
- 42.28M
Market Scanner’s AI analysis of Filana Therapeutics, Inc. (FLNA), updated September 2026: Filana Therapeutics' simufilam clinical hold lifted, driving market attention amid ongoing net losses and bearish technicals.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Filana Therapeutics, Inc. (FLNA) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Filana Therapeutics' simufilam clinical hold lifted, driving market attention amid ongoing net losses and bearish technicals.
Recent analyses for Filana Therapeutics, Inc. (FLNA) covered the lifting of the FDA clinical hold on its simufilam, enabling a Phase 2a study initiation. This development coincided with the company's Q2 2026 financial results and a business update, leading to increased market activity. However, the reports also noted persistent net losses and a negative return on equity, alongside bearish technical indicators such as trading below key moving averages and negative MACD.
FLNA news & sentiment
News reports highlighted the FDA's decision to lift the clinical hold on simufilam, a development that increased market attention. Social media discussions were not covered in the provided notes.
FLNA technical picture
The stock price traded below its 50-day and 200-day simple moving averages, indicating a downtrend relative to medium and long-term benchmarks. Momentum indicators like MACD signaled bearish momentum, while RSI and MFI suggested weak buying pressure and approached oversold territory. The price remained above the lower Bollinger Band, indicating some support.
Fundamentals
Filana Therapeutics, Inc. (FLNA) reported a market capitalization of $49,757,132. The company has consistently reported net losses across all periods, with a negative Return on Equity (ROE) TTM of -55.8% and a negative Gross Profit TTM of -15,655,000.
Factors discussed — upside
- FDA lifting clinical hold on simufilam for Phase 2a study in TSC-related epilepsy
- Increased market attention indicated by 'Most Active Stocks' headline
Factors discussed — risks
- Consistent net losses reported across all periods
- Negative Return on Equity (ROE) TTM of -55.8%
- Stock trading below 50-day and 200-day moving averages
- Bearish MACD momentum signal
- RSI and MFI approaching oversold territory, indicating weak buying pressure
- Clinical trial progress
- Financial performance
- Technical indicators
- Market attention
Summary updated .
FLNA technical indicators
Common technical indicators for FLNA, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.91 | Price below |
| 10-day exponential moving average | 0.78 | Price above |
| Relative strength index (14-day) | 54.74 | Neutral |
| MACD line (12/26/9) | -0.0512 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.65 – 0.98 | Price inside the bands |
Analyses
Recent FLNA.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Filana Therapeutics, Inc.?
- The bull case centers on the FDA lifting its clinical hold on simufilam, permitting the initiation of a Phase 2a study for TSC-related epilepsy. This development, alongside increased market attention, presents a significant positive catalyst for the company.
- What are the risks for Filana Therapeutics, Inc.?
- The company faces risks including consistent net losses across all reported periods and a negative Return on Equity. Technical indicators suggest bearish momentum, with the stock trading below key moving averages and RSI/MFI approaching oversold levels, signaling weak buying pressure.
- Is Filana Therapeutics, Inc. bullish or bearish?
- Recent AI analyses of Filana Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case centers on the FDA lifting its clinical hold on simufilam, permitting the initiation of a Phase 2a study for TSC-related epilepsy. This development, alongside increased market attention, presents a significant positive catalyst for the company. Discussed risks: The company faces risks including consistent net losses across all reported periods and a negative Return on Equity. Technical indicators suggest bearish momentum, with the stock trading below key moving averages and RSI/MFI approaching oversold levels, signaling weak buying pressure. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Filana Therapeutics, Inc.?
- News reports highlighted the FDA's decision to lift the clinical hold on simufilam, a development that increased market attention. Social media discussions were not covered in the provided notes.
- How does Market Scanner analyse Filana Therapeutics, Inc.?
- Every analysis of Filana Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh FLNA.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.